Treatment options for postmenopausal osteoporosis
نویسندگان
چکیده
منابع مشابه
Treatment options for postmenopausal osteoporosis
Correspondence: Garry M Walsh Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom To serve our readership better, future editions of Therapeutics and Clinical Risk Management will once again feature the Editor’s comments and views on some of the articles published in that issue of ...
متن کاملPostmenopausal Osteoporosis: Current and Future Treatment Options
primarily driven by hospitalizations related to fractures resulting from osteoporosis; costs range from $15,500 for any osteoporosis-related hospitalization to $17,383 for an osteoporosis fracture-related admission. In the absence of a fragility fracture, a diagnosis of osteoporosis can be made with a measurement of BMD. The expression of BMD, compared with the reference mean, is known as the T...
متن کاملTreatment of postmenopausal osteoporosis.
The aim of treatment of postmenopausal osteoporosis is to reduce the frequency of vertebral and non-vertebral fractures (especially at the hip), which are responsible for morbidity associated with the disease. Results of large placebo controlled trials have shown that alendronate, raloxifene, risedronate, the 1-34 fragment of parathyroid hormone, and nasal calcitonin, greatly reduce the risk of...
متن کاملDenosumab (prolia) for treatment of postmenopausal osteoporosis.
Data on the long-term safety of denosumab are limited; the largest clinical trial enrolled approximately 7,800 women and followed them for three years.2 The most serious safety issue is the risk of hypocalcemia, which occurs in about 2 percent of women who receive Prolia.1 The risk is higher in patients with renal impairment. Denosumab is contraindicated in patients with preexisting hypocalcemi...
متن کاملTreatment options for thalassemia patients with osteoporosis.
Osteoporosis represents a prominent cause of morbidity in patients with thalassemia. The delay in sexual maturation, the presence of diabetes and hypothyroidism, the parathyroid gland dysfunction, the progressive marrow expansion, the iron toxicity on osteoblasts, the iron chelators, and the deficiency of growth hormone or insulin growth factors have been identified as major causes of osteoporo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutics and Clinical Risk Management
سال: 2012
ISSN: 1178-203X
DOI: 10.2147/tcrm.s36280